Novo Nordisk plans Phase III study of oral semaglutide in obesity

The newly announced 68-week global study, planned to start in the second half of 2021, will investigate the efficacy and safety of oral semaglutide versus placebo in approximately 1,000 people with obesity or overweight with comorbidities.

PharmaTimes